Post-traumatic Stress Disorder Treatment Market to surpass US$ 1,380.0 Million by 2028 - Coherent Market Insights

Global Post-traumatic Stress Disorder Treatment Market, by Drug Type (Antidepressants, Monoamine Oxidase, Antipsychotics or Second generation Antipsychotics, Beta-blockers, Benzodiazepines, and Others), by End user (Adult and Children), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 990.7 million in 2021 and is expected to exhibit a CAGR of 4.2% during the forecast period (2022-2028), as highlighted in a new report published by Coherent Market Insights.

Global Post-traumatic Stress Disorder treatment market- Impact of Coronavirus (COVID-19) Pandemic.

Lockdown in various countries due to the coronavirus pandemic has placed an economic burden on the private healthcare sector. Due to this, the healthcare providers are facing challenges with regards to declining outpatient visits, manpower, equipment, consumables, and other resources to ensure safety in treatment of patients. The people who were getting infected by corona virus were also having potential symptoms of post-trauma stress disorders. Patients being admitted to the hospitals experienced social isolation, physical discomfort and fear of survival. According to American Psychiatric Association, these exposures increased the risk of PTSD. The patients who were hospitalized for treatment were not allowed immediately socially as they need to get quarantined.

The increasing number of product launches, clinical trials, collaborations and partnerships strategies adopted by key players are the major factors which are expected to drive growth of the global post-traumatic stress disorder treatment market during the forecast period.

The increasing approvals of drugs by regulatory bodies is expected to contribute significantly to the global post-traumatic stress disorder treatment’s market growth over the forecast period. For instance in 2016, US Food and Drug Administration (FDA) has given the clearance to phase 3 trials of MDMA to treat post-traumatic stress disorder, which is the final phase of drug validation.  The treatment involves giving patients the drug just three times once in a month, during long talking therapy sessions, interspersed with weekly sessions without the drug.

Key players in the global post-traumatic stress disorder treatment market are focused on gaining approvals from regulatory bodies which is expected to drive growth of the market during the forecast period. For instance, on November 4, 2019, Bionomics limited, a global clinical-stage biopharmaceutical company, discovering and developing a pipeline of novel drug candidates targeting ion channels, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the BNC210 development program for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stressor-related disorders.

Browse 36 Market Data Tables and 33 Figures spread through 183 Pages and in-depth TOC on Global Post-traumatic Stress Disorder Treatment Market, by Drug Type (Antidepressants, Monoamine Oxidase, Antipsychotics or Second generation Antipsychotics, Beta-blockers, Benzodiazepines, and Others), by End User (Adult and Children), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2028

To know the latest trends and insights related to Global Post-traumatic Stress Disorder Treatment Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/post-traumatic-stress-disorder-treatment-market-4433

The rising adoption of inorganic growth strategies such as mergers and acquisitions by major companies is expected to drive growth of the global post-traumatic stress disorder treatment market. For instance, in October 2020, Jazz Pharmaceuticals plc and SpringWorks Therapeutics, Inc. announced that Jazz Pharmaceuticals Ireland Limited and SpringWorks have entered into an asset purchase and exclusive license agreement under which Jazz has acquired SpringWorks' fatty acid amide hydrolase ("FAAH") inhibitor program including PF-04457845 in US$ 375 million. Jazz will initially focus on developing PF-04457845 for the potential treatment of post-traumatic stress disorder ("PTSD") and associated symptoms. PF-04457845 represents an innovative approach to treating PTSD with a novel mechanism of action that has the potential to address multiple core symptoms of the disease, including fear extinction, anxiety, and disrupted sleep architecture.

Key Takeaways of the Global Post-traumatic Stress Disorder Treatment Market:

• The global post-traumatic stress disorder treatment market is expected to exhibit a CAGR of 4.2% during the forecast period, owing to the increasing number of product approvals and launches by key players.
• Among drug type, antidepressants drugs segment is expected to hold major revenue share in 2028, owing to launch of new antidepressants drugs. For instance, on March 5, 2020, the Food and Drug Administration (FDA) approved the first new medication for major depression in decades. The drug is a nasal spray called esketamine, derived from ketamine—an anesthetic that has made waves for its surprising antidepressant effect. As treatment with esketamine might be helpful to patients with treatment-resistant depression, the US FDA accelerated the approval process to make it more quickly available. In one study of US Department of Veterans Affairs, 70 percent of patients with treatment-resistant depression, who started on an oral antidepressant and intranasal esketamine, improved as compared to just over half in the group that did not receive the medication.
• Major players operating in the global post-traumatic stress disorder treatment market includes Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, Sun Pharmaceuticals Pvt Ltd, Bristol-Myers Squibb, Johnson and Johnson, Pfizer Inc., Aurobindo , Amneal Pharmaceuticals LLC, Apotex Inc., Teva Pharmaceuticals Pvt Ltd., Mylan Pharmaceuticals, and Bausch Health Companies Inc.